INmune Bio Financials
| INMB Stock | USD 8.43 0.72 7.87% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.05 | 2.1631 |
|
|
The financial analysis of INmune Bio is a critical element in measuring its lifeblood. The essential information of the day-to-day investment outlook for INmune Bio includes many different criteria found on its balance sheet. For example, investors should never minimize INmune Bio's ability to pay suppliers or employees on time, making sure interest payments are not accumulating or correctly timing where and how to re-invest extra cash. Any individual investor needs to monitor INmune Bio's cash flow, debt, and profitability to effectively and accurately make more informed decisions on whether to invest in INmune Bio.
Net Income |
|
With this module, you can analyze INmune financials for your investing period. You should be able to track the changes in INmune Bio individual financial statements over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.
INmune | Select Account or Indicator |
Understanding current and past INmune Bio Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of INmune Bio's financial statements are interrelated, with each one affecting the others. For example, an increase in INmune Bio's assets may result in an increase in income on the income statement.
The data published in INmune Bio's official financial statements usually reflect INmune Bio's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of INmune Bio. For example, before you start analyzing numbers published by INmune accountants, it's critical to develop an understanding of what INmune Bio's liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of INmune Bio's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, INmune Bio's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in INmune Bio's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of INmune Bio. Please utilize our Beneish M Score to check the likelihood of INmune Bio's management manipulating its earnings.
INmune Bio Stock Summary
INmune Bio competes with Home Federal, Betterware, Provident Bancorp, Heartland Financial, and Nordea Bank. INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patients innate immune system to treat disease. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida. Inmune Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 10 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US45782T1051 |
| CUSIP | 45782T105 |
| Location | California; U.S.A |
| Business Address | 225 NE Mizner |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | NYSE Composite |
| Website | www.inmunebio.com |
| Phone | 858 964 3720 |
| Currency | USD - US Dollar |
You should never invest in INmune Bio without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of INmune Stock, because this is throwing your money away. Analyzing the key information contained in INmune Bio's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
INmune Bio Key Financial Ratios
Generally speaking, INmune Bio's financial ratios allow both analysts and investors to convert raw data from INmune Bio's financial statements into concise, actionable information that can be used to evaluate the performance of INmune Bio over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that INmune Bio reports annually and quarterly.| Return On Equity | -0.61 | ||||
| Operating Margin | (299.25) % | ||||
| Price To Sales | 1,208 X |
INmune Bio Key Balance Sheet Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 24.5M | 40.7M | 99.9M | 81.8M | 57.0M | 41.6M | |
| Net Tangible Assets | 7.1M | 22.2M | 63.7M | 43.6M | 50.1M | 52.6M | |
| Retained Earnings | (21.3M) | (33.4M) | (63.7M) | (91.0M) | (121.0M) | (115.0M) | |
| Accounts Payable | 692.1K | 1.6M | 3.8M | 5.2M | 7.9M | 8.3M | |
| Cash | 7.0M | 22.0M | 74.8M | 52.2M | 35.8M | 23.6M | |
| Capital Surpluse | 44.8M | 72.1M | 143.9M | 151.8M | 174.6M | 183.3M | |
| Total Liab | 860.5K | 1.9M | 19.7M | 21.7M | 18.9M | 19.8M | |
| Total Current Assets | 7.8M | 24.0M | 82.6M | 64.7M | 39.9M | 27.2M | |
| Common Stock | 8.7K | 10.8K | 13.5K | 18K | 817K | 857.9K | |
| Net Debt | (6.8M) | (21.8M) | (59.6M) | (36.8M) | (25.4M) | (26.7M) | |
| Net Receivables | 645.4K | 1.8M | 5.5M | 8.5M | 2.4M | 2.8M | |
| Other Current Assets | 769.3M | 2.0B | 7.8M | 4.0M | 1.7M | 1.6M | |
| Net Invested Capital | 23.6M | 38.8M | 94.7M | 74.8M | 48.1M | 49.4M | |
| Net Working Capital | 7.1M | 22.2M | 78.2M | 53.8M | 21.5M | 29.0M |
INmune Bio Key Cash Accounts
Cash flow analysis captures how much money flows into and out of INmune Bio. It measures of how well INmune is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money INmune Bio brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money INmune had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what INmune Bio has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | 6.8M | 15.0M | 52.8M | (22.7M) | (16.3M) | (15.5M) | |
| Net Income | (7.7M) | (12.1M) | (30.3M) | (27.3M) | (30.0M) | (28.5M) | |
| End Period Cash Flow | 7.0M | 22.0M | 74.8M | 52.2M | 35.8M | 23.6M | |
| Change To Netincome | 4.1M | 3.1M | 4.8M | 7.1M | 8.2M | 8.6M | |
| Free Cash Flow | (5.4M) | (8.9M) | (43.5M) | (22.7M) | (12.0M) | (12.6M) | |
| Other Non Cash Items | (1.5M) | (3.0M) | 126K | 328K | 224K | 235.2K |
INmune Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining INmune Bio's current stock value. Our valuation model uses many indicators to compare INmune Bio value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across INmune Bio competition to find correlations between indicators driving INmune Bio's intrinsic value. More Info.INmune Bio is currently regarded as number one stock in return on equity category among related companies. It is currently regarded as number one stock in return on asset category among related companies . At present, INmune Bio's Return On Equity is projected to slightly decrease based on the last few years of reporting.Comparative valuation analysis is a catch-all model that can be used if you cannot value INmune Bio by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for INmune Bio's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the INmune Bio's earnings, one of the primary drivers of an investment's value.INmune Bio Systematic Risk
INmune Bio's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. INmune Bio volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty-four with a total number of output elements of thirty-seven. The Beta measures systematic risk based on how returns on INmune Bio correlated with the market. If Beta is less than 0 INmune Bio generally moves in the opposite direction as compared to the market. If INmune Bio Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one INmune Bio is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of INmune Bio is generally in the same direction as the market. If Beta > 1 INmune Bio moves generally in the same direction as, but more than the movement of the benchmark.
About INmune Bio Financials
What exactly are INmune Bio Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include INmune Bio's income statement, its balance sheet, and the statement of cash flows. Potential INmune Bio investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although INmune Bio investors may use each financial statement separately, they are all related. The changes in INmune Bio's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on INmune Bio's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.Steps to analyze INmune Bio Financials for Investing
There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt-to-equity ratio because this number will tell you how much risk it has. If a company such as INmune Bio is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of INmune has grown by more than 25% over the last five years, then there is a good chance that it will continue growing by at least 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it. In summary, you can determine if INmune Bio's financials are consistent with your investment objective using the following steps:- Review INmune Bio's balance sheet accounts, such as liabilities and equity, to understand its overall financial position.
- Analyze the income statement and examine the company's revenue, expenses, and profits over time to determine its financial performance.
- Study the cash flow inflows and outflows to understand INmune Bio's liquidity and solvency.
- Look at the growth rates in revenue, earnings, and cash flow over time to determine its potential for future growth.
- Compare INmune Bio's financials to those of its peers to see how it stacks up and identify any potential red flags.
- Use valuation ratios to evaluate the company's financials using commonly used ratios such as the price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and enterprise value-to-earnings before interest, taxes, depreciation, and amortization (EV/EBITDA) ratio to determine if INmune Bio's stock is overvalued or undervalued.
Today, most investors in INmune Bio Stock are looking for potential investment opportunities by analyzing not only static indicators but also various INmune Bio's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of INmune Bio growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
INmune Bio April 18, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of INmune Bio help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of INmune Bio. We use our internally-developed statistical techniques to arrive at the intrinsic value of INmune Bio based on widely used predictive technical indicators. In general, we focus on analyzing INmune Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build INmune Bio's daily price indicators and compare them against related drivers.
| Information Ratio | (0.12) | |||
| Maximum Drawdown | 22.83 | |||
| Value At Risk | (7.76) | |||
| Potential Upside | 6.77 |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in INmune Bio. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. For information on how to trade INmune Stock refer to our How to Trade INmune Stock guide.You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Complementary Tools for INmune Stock analysis
When running INmune Bio's price analysis, check to measure INmune Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy INmune Bio is operating at the current time. Most of INmune Bio's value examination focuses on studying past and present price action to predict the probability of INmune Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move INmune Bio's price. Additionally, you may evaluate how the addition of INmune Bio to your portfolios can decrease your overall portfolio volatility.
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges |
Is INmune Bio's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of INmune Bio. If investors know INmune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about INmune Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.67) | Revenue Per Share 0.009 | Quarterly Revenue Growth (0.71) | Return On Assets (0.27) | Return On Equity (0.61) |
The market value of INmune Bio is measured differently than its book value, which is the value of INmune that is recorded on the company's balance sheet. Investors also form their own opinion of INmune Bio's value that differs from its market value or its book value, called intrinsic value, which is INmune Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because INmune Bio's market value can be influenced by many factors that don't directly affect INmune Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between INmune Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if INmune Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, INmune Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.